Condition: MDS · Myelodysplastic Syndromes · Sponsor: Groupe Francophone des Myelodysplasies
Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA
This description comes directly from the study's public registry record.
Fatiha CHERMAT · +33 1 71 20 70 59 · fatiha.chermat-ext@aphp.fr
Karine LEMARIE · +33 1 71 20 70 54 · karine.lemarie-ext@aphp.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens-Picardie | Amiens, France | Recruiting |
| Clinique de l'Europe | Amiens, France | Not Yet Recruiting |
| CHU Angers | Angers, France | Recruiting |
| Centre Hospitalier Victor Dupouy | Argenteuil, France | Recruiting |
| CH Henri Duffaut d'Avignon | Avignon, France | Recruiting |
| Centre Hospitalier de la Côte Basque | Bayonne, France | Not Yet Recruiting |
| Hôpital Avicenne | Bobigny, France | Recruiting |
| Hôpital Privé Sévigné | Cesson-Sévigné, France | Recruiting |
| CHU de Grenoble | Grenoble, France | Recruiting |
| Centre Hospitalier de Versailles | Le Chesnay, France | Not Yet Recruiting |
| Hôpital Bicêtre | Le Kremlin-Bicêtre, France | Recruiting |
| CH Le Mans | Le Mans, France | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05181735